Correlation of the biological clock gene PER1 with ferroptosis in nasopharyngeal carcinoma

References

• Bellet MM, Stincardini C, Costantini C, Gargaro M, Pieroni S, Castelli M, Piobbico D, Sassone-Corsi P, Della-Fazia MA, Romani L, et al. 2021. The circadian protein PER1 modulates the cellular response to anticancer treatments. Int J Mol Sci. 22(6):2974. doi:10.3390/ijms22062974.
   PubMed Web of Science ®Google Scholar
• Bossi P, Chan AT, Licitra L, Trama A, Orlandi E, Hui EP, Halámková J, Mattheis S, Baujat B, Hardillo J, et al. 2021. Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 32(4):452–465. doi:10.1016/j.annonc.2020.12.007.
   PubMed Web of Science ®Google Scholar
• Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. 2019. Nasopharyngeal carcinoma. Lancet. 394(10192):64–80. doi: 10.1016/S0140-6736(19)30956-0.
   PubMed Web of Science ®Google Scholar
• Chen M, Tan AH, Li J. 2023. Curcumin represses colorectal cancer cell proliferation by triggering ferroptosis via PI3K/Akt/mTOR Signaling. Nutr Cancer. 75(2):726–733. doi: 10.1080/01635581.2022.2139398.
   PubMed Web of Science ®Google Scholar
• Chen X, Yu C, Kang R, Kroemer G, Tang D. 2021. Cellular degradation systems in ferroptosis. Cell Death Differ. 28(4):1135–1148. doi: 10.1038/s41418-020-00728-1.
   PubMed Web of Science ®Google Scholar
• Chen M, Zhang L, Liu X, Ma Z, Lv L. 2021. PER1 is a prognostic biomarker and correlated with immune infiltrates in ovarian cancer. Front Genet. 17(12):697459–697471. doi: 10.3389/fgene.2021.697471.
   Google Scholar
• Ding X, Zhang WJ, You R, Zou X, Wang Z-Q, Ouyang Y-F, Peng L, Liu Y-P, Duan C-Y, Yang Q, et al. 2023. Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase II study. J Clin Oncol. 41(14):2571–2582. doi: 10.1200/JCO.22.01450.
   PubMed Web of Science ®Google Scholar
• Gong X, Tang H, Yang K. 2021. PER1 suppresses glycolysis and cell proliferation in oral squamous cell carcinoma via the PER1/RACK1/PI3K signaling complex. Cell Death Disease. 12(3):276. doi: 10.1038/s41419-021-03563-5.
   PubMed Web of Science ®Google Scholar
• Guo X, Li K, Jiang W, Hu Y, Xiao W, Huang Y, Feng Y, Pan Q, Wan R. 2020. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner. Mol Cancer. 19(1):91. doi: 10.1186/s12943-020-01158-w.
   PubMed Web of Science ®Google Scholar
• Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, Galeas J, Dhruv HD, Berens ME, Schreiber SL, et al. 2017. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 551(7679):247–250. doi:10.1038/nature24297.
   PubMed Web of Science ®Google Scholar
• Hassannia B, Vandenabeele P, Vanden Berghe T. 2019. Targeting ferroptosis to iron out cancer. Cancer Cell. 35(6):830–849. doi: 10.1016/j.ccell.2019.04.002.
   PubMed Web of Science ®Google Scholar
• Hernández-Rosas F, Hernández-Oliveras A, Flores-Peredo L, Rodr?guez G, Zarain‑Herzberg ?, Caba M, Santiago‑Garc?a J. 2018. Histone deacetylase inhibitors induce the expression of tumor suppressor genes PER1 and Per2 in human gastric cancer cells. Oncol Lett. 16(2):1981–1990. doi: 10.3892/ol.2018.8851.
   PubMed Web of Science ®Google Scholar
• Hsu CM, Lin SF, Lu CT, Lin P-M, Yang M-Y. 2012. Altered expression of circadian clock genes in head and neck squamous cell carcinoma. Tumour Biol. 33(1):149–155. doi: 10.1007/s13277-011-0258-2.
   PubMed Web of Science ®Google Scholar
• Huang S, Cao B, Zhang J, Feng Y, Wang L, Chen X, Su H, Liao S, Liu J, Yan J, et al. 2021. Induction of ferroptosis in human nasopharyngeal cancer cells by cucurbitacin B: molecular mechanism and therapeutic potential. Cell Death Disease. 12(3):237. doi:10.1038/s41419-021-03516-y.
   PubMed Web of Science ®Google Scholar
• Jiang X, Stockwell BR, Conrad M. 2021. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 22(4):266–282. doi: 10.1038/s41580-020-00324-8.
   PubMed Web of Science ®Google Scholar
• Koppula P, Zhuang L, Gan B. 2021. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 12(8):599–620. doi: 10.1007/s13238-020-00789-5.
   PubMed Web of Science ®Google Scholar
• Lee AWM, Ng WT, Chan JYW, Corry J, Mäkitie A, Mendenhall WM, Rinaldo A, Rodrigo JP, Saba NF, Strojan P, et al. 2019. Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat Rev. 79:101881–101890. doi: 10.1016/j.ctrv.2019.101890.
   Web of Science ®Google Scholar
• Li HX. 2019. The role of circadian clock genes in tumors. Onco Targets Ther. 12:3645–3660. doi: 10.2147/OTT.S203144.
   PubMed Web of Science ®Google Scholar
• Liang C, Zhang X, Yang M, Dong X. 2019. Recent progress in ferroptosis inducers for cancer therapy. Adv Mater. 31(51):e1904197. doi: 10.1002/adma.201904197.
   PubMed Web of Science ®Google Scholar
• Li J, Cao F, Yin HL, Huang Z-J, Lin Z-T, Mao N, Sun B, Wang G. 2020. Ferroptosis: past, present and future. Cell Death Disease. 11(2):88. doi: 10.1038/s41419-020-2298-2.
   PubMed Web of Science ®Google Scholar
• Li Y, Chen F, Chen J, Chan S, He Y, Liu W, Zhang G. 2020. Disulfiram/Copper induces antitumor activity against both nasopharyngeal cancer cells and cancer-associated fibroblasts through ROS/MAPK and ferroptosis pathways. Cancers Basel. 12(1):138. doi: 10.3390/cancers12010138.
   PubMed Web of Science ®Google Scholar
• Li XY, Luo DH, Guo L, Mo H-Y, Sun R, Guo S-S, Liu L-T, Yang Z-C, Yang J-H, Qiu F, et al. 2022. Deintensified chemoradiotherapy for pretreatment Epstein-Barr virus DNA-Selected low-risk locoregionally advanced nasopharyngeal carcinoma: a phase II randomized noninferiority trial. J Clin Oncol. 40(11):1163–1173. doi:10.1200/JCO.21.01467.
   PubMed Web of Science ®Google Scholar
• Lin YS, Tsai KL, Chen JN, Wu C-S. 2020. Mangiferin inhibits lipopolysaccharide-induced epithelial-mesenchymal transition (EMT) and enhances the expression of tumor suppressor gene PER1 in non-small cell lung cancer cells. Environ Toxicol. 35(10):1070–1081. doi: 10.1002/tox.22943.
   PubMed Web of Science ®Google Scholar
• Liu Y, Hao J, Yuan G, Wei M, Bu Y, Jin T, Ma L. 2021. PER1 as a tumor suppressor attenuated in the malignant phenotypes of breast cancer cells. Int J Gen Med. 14:7077–7087. doi: 10.2147/IJGM.S328184.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang C, Wang J, Hu W, Feng Z. 2020. The regulation of ferroptosis by tumor suppressor p53 and its pathway. Int J Mol Sci. 21(21):8387. doi: 10.3390/ijms21218387.
   PubMed Web of Science ®Google Scholar
• Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, Li B. 2019. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 12(1):34. doi: 10.1186/s13045-019-0720-y.
   PubMed Web of Science ®Google Scholar
• Seibt TM, Proneth B, Conrad M. 2019. Role of GPX4 in ferroptosis and its pharmacological implication. Free Radic Biol Med. 133:144–152. doi: 10.1016/j.freeradbiomed.2018.09.014.
   PubMed Web of Science ®Google Scholar
• Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascón S, Hatzios SK, Kagan VE, et al. 2017. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 171(2):273–285. doi:10.1016/j.cell.2017.09.021.
   PubMed Web of Science ®Google Scholar
• Sulli G, Lam MTY, Panda S. 2019. Interplay between circadian clock and cancer: new frontiers for cancer treatment. Trends Cancer. 5(8):475–494. doi: 10.1016/j.trecan.2019.07.002.
   PubMed Web of Science ®Google Scholar
• Takahashi JS. 2017. Transcriptional architecture of the mammalian circadian clock. Nat Rev Genet. 18(3):164–179. doi: 10.1038/nrg.2016.150.
   PubMed Web of Science ®Google Scholar
• Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, Kang R, Tang D. 2016. Ferroptosis: process and function. Cell Death Differ. 23(3):369–379. doi: 10.1038/cdd.2015.158.
   PubMed Web of Science ®Google Scholar
• Yang M, Chen P, Liu J, Zhu S, Kroemer G, Klionsky DJ, Lotze MT, Zeh HJ, Kang R, Tang D. 2019. Clockophagy is a novel selective autophagy process favoring ferroptosis. Sci Adv. 5(7):eaaw2238. doi: 10.1126/sciadv.aaw2238.
   PubMed Web of Science ®Google Scholar
• Yang Y, Tang H, Zheng J, Yang K. 2022. The PER1/HIF-1alpha negative feedback loop promotes ferroptosis and inhibits tumor progression in oral squamous cell carcinoma. Transl Oncol. 18:101360. doi: 10.1016/j.tranon.2022.101360.
   PubMed Web of Science ®Google Scholar
• Yang G, Yang Y, Tang H, Yang K. 2020. Loss of the clock gene PER1 promotes oral squamous cell carcinoma progression via the AKT/mTOR pathway. Cancer Sci. 111(5):1542–1554. doi: 10.1111/cas.14362.
   PubMed Web of Science ®Google Scholar
• Yi J, Zhu J, Wu J, Thompson CB, Jiang X. 2020. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferro-ptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci U S A. 117(49):31189–31197. doi: 10.1073/pnas.2017152117.
   PubMed Web of Science ®Google Scholar
• Yuan L, Li S, Chen Q, Xia T, Luo D, Li L, Liu S, Guo S, Liu L, Du C, et al. 2022. EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma. Cell Death Differ. 29(8):1513–1527. doi:10.1038/s41418-022-00939-8.
   PubMed Web of Science ®Google Scholar
• Zeng C, Lin J, Zhang K, Ou H, Shen K, Liu Q, Wei Z, Dong X, Zeng X, Zeng L, et al. 2022. SHARPIN promotes cell proliferation of cholangiocarcinoma and inhibits ferroptosis via p53/ SLC7A11 / GPX4 signaling. Cancer Sci. 113(11):3766–3775. doi:10.1111/cas.15531.
   PubMed Web of Science ®Google Scholar